Recombinant Thymidine Phosphorylase antibody (full length)
Quick Overview for Recombinant Thymidine Phosphorylase antibody (full length) (ABIN7879145)
Target
See all Thymidine Phosphorylase (TYMP) AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
Clone
-
-
Binding Specificity
- full length
-
Purpose
- Recombinant Thymidine Phosphorylase Antibody / PD-ECGF (azide and preservative free)
-
Purification
- Protein A affinity chromatography
-
Immunogen
- Human recombinant full length protein was used as the immunogen for this recombinant Thymidine Phosphorylase antibody.
-
Isotype
- IgG, kappa
-
-
-
-
Application Notes
- The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the recombinant Thymidine Phosphorylase antibody to be titered up or down for optimal performance.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store the recombinant Thymidine Phosphorylase antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- Thymidine Phosphorylase (TYMP)
-
Alternative Name
- Thymidine Phosphorylase
-
Background
- Recognizes a 485 amino acid protein (55 kDa monomer / 110 kDa homodimer), identified as platelet-derived endothelial growth factor (PD-ECGF), also called Thymidine Phosphorylase (TP, Tymp) or Gliostatin. In the presence of inorganic orthophosphate, it catalyzes the reversible phospholytic cleavage of thymidine and deoxyuridine to their corresponding bases and 2-deoxyribose-1-phosphate. It is both chemotactic and mitogenic for endothelial cells and a non-heparin binding angiogenic factor present in platelets. Its enzymatic activity is crucial for angiogenic activity (metabolite is angiogenic). Higher levels of serum TP/PD-ECGF are observed in cancer patients. It is also involved in transformation of fluoropyrimidines, cytotoxic agents used in the treatment of a variety of malignancies, into active cytotoxic metabolites (e.g. 5 -deoxy-5-fluorouridine to 5-FU). High intra-cellular levels of TP/PD-ECGF are associated with increased chemosensitivity to such antimetabolites.
-
UniProt
- P19971
-
Pathways
- Signaling Events mediated by VEGFR1 and VEGFR2
Target
-